Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

• Main Authors: Ho, Gwo Fuang, Chai, Chee Shee, Alip, Adlinda, A. Wahid, Mohd Ibrahim, Abdullah, Matin Mellor, Foo, Yoke Ching, How, Soon Hin, Zaatar, Adel, Lam, Kai Seng, Leong, Kin Wah, Low, John Seng Hooi, Md Yusof, Mastura, Lee, Erica Chai Yong, Toh, Yok Yong, Liam, Chong Kin
• Format: Article
• Language: English; English
• Published: BioMed Central Ltd. 2019
• Subjects: L Education (General); RC Internal medicine; RC731 Specialties of Internal Medicine-Diseases of The Respiratory System
• Online Access: http://irep.iium.edu.my/86185/1/HSH2020.pdf; http://irep.iium.edu.my/86185/7/Scopus%20-%20Document%20details.pdf; http://irep.iium.edu.my/86185/; https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6107-1; https://doi.org/10.1186/s12885-019-6107-1

Abstract Background: This study aimed to evaluate the efficacy, side effects and resistance mechanisms of first-line afatinib in a real-world setting. Methods: This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant...